JP2016527901A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527901A5
JP2016527901A5 JP2016534802A JP2016534802A JP2016527901A5 JP 2016527901 A5 JP2016527901 A5 JP 2016527901A5 JP 2016534802 A JP2016534802 A JP 2016534802A JP 2016534802 A JP2016534802 A JP 2016534802A JP 2016527901 A5 JP2016527901 A5 JP 2016527901A5
Authority
JP
Japan
Prior art keywords
test method
cells
mammal
cancer
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016534802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527901A (ja
JP6640086B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2014/017515 external-priority patent/WO2014130741A2/en
Application filed filed Critical
Priority claimed from PCT/US2014/050773 external-priority patent/WO2015023694A2/en
Publication of JP2016527901A publication Critical patent/JP2016527901A/ja
Publication of JP2016527901A5 publication Critical patent/JP2016527901A5/ja
Priority to JP2019152467A priority Critical patent/JP6902577B2/ja
Application granted granted Critical
Publication of JP6640086B2 publication Critical patent/JP6640086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016534802A 2013-08-12 2014-08-12 腫瘍成長を増強する方法 Active JP6640086B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019152467A JP6902577B2 (ja) 2013-08-12 2019-08-23 腫瘍成長を増強する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361865092P 2013-08-12 2013-08-12
US61/865,092 2013-08-12
PCT/US2014/017515 WO2014130741A2 (en) 2013-02-20 2014-02-20 Nme inhibitors and methods of using nme inhibitors
USPCT/US2014/017515 2014-02-20
PCT/US2014/050773 WO2015023694A2 (en) 2013-08-12 2014-08-12 Method for enhancing tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019152467A Division JP6902577B2 (ja) 2013-08-12 2019-08-23 腫瘍成長を増強する方法

Publications (3)

Publication Number Publication Date
JP2016527901A JP2016527901A (ja) 2016-09-15
JP2016527901A5 true JP2016527901A5 (enExample) 2017-09-28
JP6640086B2 JP6640086B2 (ja) 2020-02-05

Family

ID=52468797

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534802A Active JP6640086B2 (ja) 2013-08-12 2014-08-12 腫瘍成長を増強する方法
JP2019152467A Active JP6902577B2 (ja) 2013-08-12 2019-08-23 腫瘍成長を増強する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019152467A Active JP6902577B2 (ja) 2013-08-12 2019-08-23 腫瘍成長を増強する方法

Country Status (8)

Country Link
EP (2) EP4233536B1 (enExample)
JP (2) JP6640086B2 (enExample)
CN (1) CN105764334B (enExample)
AU (2) AU2014306778B2 (enExample)
CA (1) CA2921187A1 (enExample)
IL (1) IL244093B (enExample)
TW (1) TWI659210B (enExample)
WO (1) WO2015023694A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515643A (ja) * 2015-09-23 2019-06-13 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞分化剤のスクリーニング方法
EP3600451B1 (en) 2017-03-29 2025-12-24 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
CN108434452A (zh) * 2018-03-13 2018-08-24 安徽瀚海博兴生物技术有限公司 一种将pd-1抗体和jmjd6联合用于制备抗癌药物的应用
AU2021297535A1 (en) 2020-06-26 2023-02-16 Minerva Biotechnologies Corporation Anti-NME antibody and method of treating cancer or cancer metastasis
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
WO2025049494A1 (en) 2023-08-29 2025-03-06 Minerva Biotechnologies Corporation Bacterial nme7 orthologs and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
JP5405824B2 (ja) * 2005-06-30 2014-02-05 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 前駆細胞及びその使用
CN101501187A (zh) * 2006-06-06 2009-08-05 田纳西大学研究基金会 富含赘生干细胞的组合物及包含其的方法
EP2109668A4 (en) * 2007-01-22 2011-10-05 Macrogenics West Inc HUMAN CANCER STEM CELLS
EP4201421A1 (en) * 2008-10-09 2023-06-28 Minerva Biotechnologies Corporation Method for inducing pluripotency in cells
JP6196163B2 (ja) * 2011-03-17 2017-09-13 ミネルバ バイオテクノロジーズ コーポレーション 多能性幹細胞を作製する方法
US10731134B2 (en) * 2011-05-27 2020-08-04 Public University Corporation Yokohama City University Production method for artificial cancer stem cell and induced differentiation method therefor
WO2013059373A2 (en) * 2011-10-17 2013-04-25 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
KR20140100938A (ko) * 2011-11-30 2014-08-18 도쿠리츠교세이호진 고쿠리츠간켄큐센터 유도 악성 줄기세포
CA2880010A1 (en) * 2012-07-24 2014-01-30 Minerva Biotechnologies Corporation Nme variant species expression and suppression
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Nme 저해제 및 nme 저해제의 사용 방법

Similar Documents

Publication Publication Date Title
AU2022209849A1 (en) Reprogrammable tnpb polypeptides and use thereof
AU2021364399A1 (en) Reprogrammable iscb nucleases and uses thereof
JP2019047818A5 (enExample)
JP7288853B2 (ja) ゲノムネットワークを構築するための方法およびその使用
MY185961A (en) Methods and compositions for gene editing in hematopoietic stem cells
AR102888A1 (es) Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47
Kanarek et al. Critical role for IL-1β in DNA damage-induced mucositis
HRP20200613T1 (hr) Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt
HRP20251062T1 (hr) Neljudske životinje koje imaju gen humaniziranog proteina za reguliranje signala
MX2015008754A (es) Caracterizacion de un medicamento relacionado con acetato de glatiramer.
EP4437094A1 (en) Reprogrammable iscb nucleases and uses thereof
WO2016007570A3 (en) Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
JP2020520680A5 (enExample)
EP4448744A2 (en) Reprogrammable fanzor polynucleotides and uses thereof
Holbrook et al. Expanding the spectrum of pancreatic cancers responsive to vesicular stomatitis virus-based oncolytic virotherapy: challenges and solutions
MacLean II et al. The RHOX homeodomain proteins regulate the expression of insulin and other metabolic regulators in the testis
Meng et al. ZFP580, a novel zinc-finger transcription factor, is involved in cardioprotection of intermittent high-altitude hypoxia against myocardial ischemia-reperfusion injury
Patrushev et al. Mutations in mitochondrial DNA and approaches for their correction
CN116583599A (zh) 可重编程IscB核酸酶及其用途
Pesce et al. Endothelial and cardiac progenitors: boosting, conditioning and (re) programming for cardiovascular repair
CN117616126A (zh) 可重新编程的tnpb多肽及其用途
WO2019050406A8 (en) New therapy for pompe disease
JP2016123339A (ja) 多能性幹細胞の品質診断方法及び診断キット、抗がん剤並びに疾患モデル動物
CN104474537B (zh) Nedl2蛋白及其编码基因在治疗先天性巨结肠疾病中的应用
EP4436592A1 (en) Reprogrammable isrb nucleases and uses thereof